A5035529325- Asthma and respiratory diseases
- COVID-19 Clinical Research Studies
- Respiratory and Cough-Related Research
- COVID-19 and healthcare impacts
- Inhalation and Respiratory Drug Delivery
- Long-Term Effects of COVID-19
- Climate Change and Health Impacts
- IL-33, ST2, and ILC Pathways
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Intensive Care Unit Cognitive Disorders
- SARS-CoV-2 and COVID-19 Research
- Diabetes Treatment and Management
- Global Health Care Issues
- Respiratory Support and Mechanisms
- Eosinophilic Esophagitis
- Delphi Technique in Research
- Kawasaki Disease and Coronary Complications
- Academic Writing and Publishing
- Occupational and environmental lung diseases
- Pediatric health and respiratory diseases
- Pancreatic function and diabetes
- Neuropeptides and Animal Physiology
- Healthcare cost, quality, practices
- Health, psychology, and well-being
- Coronary Artery Anomalies
National Institutes of Health
2025
Imperial College London
2023-2024
University of Glasgow
2020-2024
Lung Institute
2024
University of Oxford
2023
Chelsea and Westminster Hospital NHS Foundation Trust
2022
Gartnavel General Hospital
2020-2021
Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without responsive type-2 (T2)-driven eosinophilic inflammation, inappropriately high-dose might have little therapeutic benefit with increased risk of side-effects. We compared a biomarker strategy adjust using composite score T2 biomarkers (fractional exhaled nitric oxide [FENO], blood eosinophils, serum...
Abstract Mepolizumab is an anti-interleukin-5 monoclonal antibody treatment for severe eosinophilic asthma (SEA) that reduces exacerbations. Residual airway inflammation on mepolizumab may lead to persistent Oral corticosteroids have broad anti-inflammatory effects and remain the main these residual Our study aimed explore nature corticosteroid-responsiveness of after find potentially treatable inflammatory mechanisms. The MAPLE trial was a multi-centre, randomized, double-blind,...
Inhaled corticosteroids (ICS) are the cornerstone of asthma treatment and significantly improve morbidity mortality. Adverse effects oral well documented, but less is known about ICS.
BackgroundFrequent exacerbations are an important cause of morbidity in patients with severe asthma.ObjectiveOur aim was to identify factors associated frequent a large well-characterized asthma population and determine whether differed treated without maintenance oral corticosteroids (OCS).MethodsAdults from specialized centers across the United Kingdom were recruited UK Severe Asthma Registry. Demography, comorbidities physiological measurements collected. We conducted univariable...
In T2-mediated severe asthma, biologic therapies, such as mepolizumab, are increasingly used to control disease. Current biomarkers can indicate adequate suppression of T2 inflammation, but it is unclear whether they provide information about airway microbial composition. We investigated the relationships between current and profiles, characteristics associated with a ProteobacteriaHIGH profile effects mepolizumab on ecology.Microbiota sequencing was performed sputum samples obtained at...
<b>Asthma therapy, including monoclonal antibodies, was not associated with #COVID19 infection or hospitalisation in a UK severe asthma population. Shielding led to reported worsening of mental health nearly half patients contacted (47%).</b>https://bit.ly/3jImUsG
Mepolizumab inhibits IL-5 activity and reduces exacerbation frequency maintenance oral corticosteroid (OCS) dosage in patients with severe eosinophilic asthma (SEA). Some remain dependent on OCS despite anti-IL-5 treatment, suggesting residual corticosteroid-responsive mechanisms.To determine the clinical anti-inflammatory effects of SEA mepolizumab.We conducted a randomized, triple-blind, placebo-controlled crossover trial prednisolone (0.5 mg/kg/d, maximum 40 mg/d, for 14 ± 2 days) adults...
The utility of fractional exhaled nitric oxide (FENO) suppression (FeNOSuppT) to identify non-adherence inhaled corticosteroid (ICS) treatment has previously been reported, but whether it can predict clinical outcome remains unclear.We examined the FeNOSuppT in prediction progression biologic agents or discharge from specialist care.FeNOSuppT was measured at home using remote monitoring technology inhaler use alongside daily FENO measurement over 7 days. Long-term outcomes terms agent care...
Graphical abstractAbstractBackgroundMepolizumab is an anti-IL-5 mAb treatment for severe eosinophilic asthma that reduces exacerbations. Residual airway inflammation with mepolizumab therapy may lead to persistent Oral corticosteroids remain the main these residual exacerbations.ObjectiveOur study aimed explore corticosteroid responsiveness of after find potentially treatable inflammatory mechanisms beyond IL-5 pathway.MethodsThe MAPLE trial was a multicenter, randomized, double-blind,...
<h3>Background</h3> Severe asthma (SA) is a heterogenous inflammatory condition. The influence of duration in SA, and its phenotypes endotypes, unknown. <h3>Aims</h3> We investigated the relationship between lung function whether this was influenced by SA endotypes. <h3>Methods</h3> included patients aged ≥18 from Unbiased Biomarkers for Prediction Respiratory disease Outcomes (U-BIOPRED). Childhood-onset, adult-onset late-onset were defined as onset symptoms <18, ≥30 years age....
<b>Background:</b> Mepolizumab is an anti-interleukin-5 monoclonal antibody for severe eosinophilic asthma (SEA). The effects of mepolizumab, or the addition oral corticosteroids (OCS) to on molecular mechanisms in airway epithelium are poorly understood. <b>Aim:</b> Determine transcriptional mepolizumab followed by prednisolone placebo nasal patients with SEA. <b>Methods:</b> MAPLE was a randomized, double-blind, placebo-controlled crossover trial at stable state adults SEA after (Yang F,...
<h3>Background</h3> Mepolizumab is an anti-interleukin-5 monoclonal antibody for severe eosinophilic asthma (SEA). The additional effects of prednisolone to mepolizumab, on molecular mechanisms in the airways and blood are poorly understood. <h3>Aim</h3> Determine transcriptomic proteomic versus placebo patients with SEA treated mepolizumab. <h3>Methods</h3> MAPLE was a randomized, double-blind, placebo-controlled crossover trial at stable state adults after mepolizumab (Yang F, JACI Pract...
<h3>Introduction</h3> During the first wave of COVID-19 pandemic in UK there was a reduction A&E attendances and hospital admissions. Monthly excess deaths peaked April 2020; driven by COVID-19.<sup>1</sup> We investigated whether admissions due to asthma were reduced 2020 compared previous five years if this accompanied an increase deaths. <h3>Methods</h3> Five-year data obtained from Public Health Scotland time period January 2015 June 2020. Hospital admission sourced Scotland's...